Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9009 - 9016 of 12089 results
Does Invalidation of 340B Orphan Drug Rule Doom HRSA’s Guidance?
October 20, 2015| Blog| Viewpoint
Irish High Court Quashes Irish Data Protection Commission Original Schrems' Decision
October 20, 2015| Blog| Viewpoint
DOS vs USCIS: Visa Bulletin Games
October 20, 2015| Blog| Viewpoint
DHS Submits New STEM OPT Rule for Comment
October 19, 2015| Alert| Viewpoint
FTC Answers the Call for Guidance Regarding Antitrust Compliance for State Regulatory Boards Controlled by Market Participants
October 19, 2015| Alert| Viewpoint
FTC Submits Public Comments to States Considering Regulations of Cooperative Agreements Between Hospitals
October 19, 2015| Blog| Viewpoint
FTC Provides Guidance Regarding Antitrust Compliance for State Regulatory Boards
October 19, 2015| Blog| Viewpoint
Congress Contemplates Renewable Energy Tax Credits
October 16, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|